Seres Therapeutics Reports Q1 Loss, Short Cash Runway, Awaits Key Clinical Data Amid Funding Search
MCRB sits 20% above its 52-week low of $6.53.
Summary
Seres Therapeutics reported a Q1 net loss and a short cash runway through Q3 2026, intensifying its search for funding, while awaiting key clinical data for its SER-155 program.
Key Events · Financing and Capital Events · MCRB
-
Q1 Financial Results Show Net Loss
The company reported a net loss of $19.9 million for the first quarter of 2026, a significant decline from a net income of $32.7 million in the same period of 2025, largely due to the absence of a $50 million payment from Nestlé.
-
Shortened Cash Runway
As of March 31, 2026, Seres had $29.8 million in cash and cash equivalents and expects to fund operations only through the third quarter of 2026, highlighting an urgent need for additional capital.
-
Key Clinical Data Expected Soon
A clinical readout from an investigator-sponsored study evaluating SER-155 in immune checkpoint inhibitor-related enterocolitis (irEC) is anticipated in the coming weeks, representing a potential near-term catalyst.
-
Funding Sought for SER-155 Phase 2
The SER-155 program for the prevention of bloodstream infections in allo-HSCT patients is Phase 2 ready, but the company is actively seeking funding to commence the study.
Analysis · MCRB · Life Sciences
Seres Therapeutics reported a net loss of $19.9 million for Q1 2026, a significant reversal from the prior year's net income, primarily due to the absence of a $50 million payment from Nestlé. The company's cash and cash equivalents stood at $29.8 million as of March 31, 2026, with an anticipated cash runway only through the third quarter of 2026. This short runway, following a previous going concern warning, underscores the urgent need for additional capital and partnerships to advance its pipeline. While the financial situation is challenging, the company anticipates a clinical readout from an investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis in the coming weeks, which could serve as a critical near-term catalyst.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MCRB was trading at $7.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $74.1M. The 52-week trading range was $6.53 to $29.98. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.